Issatayeva, Aizhan, Farnesi, Edoardo, Cialla-May, Dana, Schmitt, Michael, Rizzi, Federica Maria Angel, Milanese, Daniel, Selleri, Stefano, and Cucinotta, Annamaria
Genomic biomarkers of cancer are based on changes in nucleic acids, which include abnormal expression levels of some miRNAs, point mutations in DNA sequences, and altered levels of DNA methylation. The presence of tumor-related nucleic acids in body fluids (blood, saliva, or urine) makes it possible to achieve a non-invasive early-stage cancer diagnosis. Currently existing techniques for the discovery of nucleic acids require complex, time-consuming, costly assays and have limited multiplexing abilities. Surface-enhanced Raman spectroscopy (SERS) is a vibrational spectroscopy technique that is able to provide molecular specificity combined with trace sensitivity. SERS has gained research attention as a tool for the detection of nucleic acids because of its promising potential: label-free SERS can decrease the complexity of assays currently used with fluorescence-based detection due to the absence of the label, while labeled SERS may outperform the gold standard in terms of the multiplexing ability. The first papers about SERS-based methods for the measurement of genomic biomarkers were written in 2008, and since then, more than 150 papers have been published. The aim of this paper is to review and evaluate the proposed SERS-based methods in terms of their level of development and their potential for liquid biopsy application, as well as to contribute to their further evolution by attracting research attention to the field. This goal will be reached by grouping, on the basis of their experimental protocol, all the published manuscripts on the topic and evaluating each group in terms of its limit of detection and applicability to real body fluids. Thus, the methods are classified according to their working principles into five main groups, including capture-based, displacement-based, sandwich-based, enzyme-assisted, and specialized protocols. [Display omitted] • SERS-based detection of miRNA level changes, DNA point mutations, and DNA methylation level alterations in body fluids have good potential for early-stage cancer diagnosis. • Biological protocols designed for the selective detection of the target DNAs/miRNAs have been reviewed and grouped into the following categories: capture, displacement, sandwich, cleavage, and specific protocols. • The protocols have been arranged according to the increasing complexity of the assays and evaluated in terms of their performance for liquid biopsy application. As a result, one-to-step protocols have shown good LODs, applicability in body fluids, and multiplexing abilities, especially for miRNA detection. • In general, labeled protocols outperform label-free assays by reaching the LODs as low as 10 − 16 M and detecting the target miRNA/DNA in the complex matrices, such as total RNAs/DNAs and real body fluids. However, the performance of the label-free protocols can be improved by developing highly sensitive SERS substrates. • Thus, there is a potential to develop relatively simple SERS-based protocols for liquid biopsy applications with promising LODs and multiplexing abilities, but more work should be conducted in this direction. [ABSTRACT FROM AUTHOR]